It was proved that TME, specific receptors, and signaling pathways can affect the clinical outcome of PD-1/PD-L1 treatment (19), Combining different immunotherapies or combining immunotherapies with other modalities may provide synergistic effects and facilitate the development of the treatment of HCC (20). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.